Parallel Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Parallel Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7	Closed	-$29	–	3945
2025 Q4	$29	Hold	7	–	–	﹤0.01%	3588
2025 Q3	$34	Buy	+7	New	+$37	﹤0.01%	3517
2025 Q2	–	Sell	-393	Closed	-$2.2K	–	3681
2025 Q1	$2.2K	Buy	393 +75	+24%	+$547	﹤0.01%	2954
2024 Q4	$2.15K	Buy	318 +156	+96%	+$1.05K	﹤0.01%	2947
2024 Q3	$1.07K	Buy	162 +160	+8,000%	+$1.15K	﹤0.01%	3019
2024 Q2	$15	Hold	2	–	–	﹤0.01%	3292
2024 Q1	$20	Hold	2	–	–	﹤0.01%	3260
2023 Q4	$20	Sell	2 -63	-97%	-$449	﹤0.01%	3279
2023 Q3	$497	Hold	65	–	–	﹤0.01%	3107
2023 Q2	$486	Buy	+65	New	+$455	﹤0.01%	3107
2023 Q1	–	Sell	-29	Closed	-$224	–	3493
2022 Q4	$224	Hold	29	–	–	﹤0.01%	3172
2022 Q3	$0	Hold	29	–	–	﹤0.01%	3448
2022 Q2	$0	Buy	+29	New	+$194	﹤0.01%	3307
2022 Q1	–	Sell	-151	Closed	-$3K	–	3235
2021 Q4	$3K	Sell	151 -249	-62%	-$4.68K	﹤0.01%	2611
2021 Q3	$9K	Buy	+400	New	+$11.3K	﹤0.01%	2131

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Parallel Advisors's RXRX Position: Q1 2026 in Review

Parallel Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 7 shares — an estimated $29 sold.

Parallel Advisors first reported a position in RXRX in Q3 2021 and held it in 15 quarters. The position peaked at $9K in Q3 2021. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Parallel Advisors reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Parallel Advisors sold 7 Recursion Pharmaceuticals shares in Q1 2026, an estimated $29.
Parallel Advisors first reported a position in Recursion Pharmaceuticals in Q3 2021 and held it in 15 quarters.
Parallel Advisors's Recursion Pharmaceuticals position peaked at $9K in Q3 2021.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.